12:59 PM EST, 01/15/2026 (MT Newswires) -- Emergent BioSolutions ( EBS ) former CEO Robert Kramer was sued by New York Attorney General Letitia James for alleged insider trading, according to a statement from the Attorney General's office.

The lawsuit claims Kramer "executed a plan" to sell his shares and received more than $10.1 million before contamination issues at Emergent's AstraZeneca ( AZN ) Covid-19 vaccine facility became public.

The company approved Kramer's trading plan in November 2020. Kramer sold his shares in January and February 2021 shortly before the company's stock price began a sustained decline.

The US Food and Drug Administration ordered a permanent halt to Emergent BioSolutions' ( EBS ) production of the AstraZeneca ( AZN ) vaccine in April 2021, according to the statement.

Emergent BioSolutions ( EBS ) will pay $900,000 in penalties and enhance its executive trading policies under the settlement. The attorney general said it is seeking damages, disgorgement of all ill-gotten gains and costs from Kramer for violating state securities laws.

Shares of Emergent BioSolutions ( EBS ) were down 7.6% in recent trading.

Price: 11.59, Change: -0.95, Percent Change: -7.58